Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02668653
Title	Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)
Acronym	QuANTUM-First
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Daiichi Sankyo Inc.
Indications	acute myeloid leukemia
Therapies	Cytarabine + Daunorubicin + Idarubicin Cytarabine + Daunorubicin + Idarubicin + Quizartinib
Age Groups:	senior \| adult
Covered Countries	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS